Free tool
FAERS Monitor: Xofluza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214410 or its brand name (Xofluza, Baloxavir Marboxil). Reports on generic versions are filed under their own applications.
Reports
2,319
Serious
1,231
53% of reports
Hospitalization
455
Death reported
136
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event547
- off label use427
- intentional product use issue283
- diarrhoea136
- vomiting132
- pneumonia115
- drug ineffective90
- nausea75
- rash70
- hyperpyrexia68
- headache64
- influenza60
- colitis ischaemic57
- pyrexia55
- cough45
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 24 |
| 2019 | 814 |
| 2020 | 652 |
| 2021 | 56 |
| 2022 | 84 |
| 2023 | 161 |
| 2024 | 123 |
| 2025 | 250 |
| 2026 | 154 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,840 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperpyrexiaSignal | 68 | 148.0 | 116.9 | 9,629 |
| colitis ischaemicSignal | 57 | 77.3 | 59.7 | 4,181 |
| intentional product use issueSignal | 283 | 29.4 | 26.3 | 7,740 |
| no adverse eventSignal | 547 | 27.5 | 25.5 | 14,000 |
| influenzaSignal | 60 | 4.9 | 3.8 | 182 |
| off label useSignal | 427 | 4.4 | 4.1 | 1,177 |
| pneumoniaSignal | 115 | 3.2 | 2.7 | 177 |
| vomitingSignal | 132 | 2.5 | 2.2 | 125 |
| diarrhoea | 136 | 1.9 | 1.6 | 60 |
| rash | 70 | 1.5 | 1.2 | 10 |
| cough | 45 | 1.5 | 1.1 | 6 |
| pyrexia | 55 | 1.4 | 1.1 | 7 |
| headache | 64 | 0.9 | 0.7 | 0 |
| nausea | 75 | 0.9 | 0.7 | 2 |
| drug ineffective | 90 | 0.6 | 0.5 | 22 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.